• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

    5/13/25 4:30:21 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    FULGENT GENETICS INC

    (Name of Issuer)


    COMMON-STOCK

    (Title of Class of Securities)


    359664109

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    359664109


    1Names of Reporting Persons

    Barclays PLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,338,024.00
    6Shared Voting Power

    427.00
    7Sole Dispositive Power

    2,338,024.00
    8Shared Dispositive Power

    427.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,338,451.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.57 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    FULGENT GENETICS INC
    (b)Address of issuer's principal executive offices:

    4399 Santa Anita Avenue
    Item 2. 
    (a)Name of person filing:

    Barclays PLC
    (b)Address or principal business office or, if none, residence:

    1 Churchill Place, London - E14 5HP
    (c)Citizenship:

    X0
    (d)Title of class of securities:

    COMMON-STOCK
    (e)CUSIP No.:

    359664109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2338451
    (b)Percent of class:

    7.57  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2338024

     (ii) Shared power to vote or to direct the vote:

    427

     (iii) Sole power to dispose or to direct the disposition of:

    2338024

     (iv) Shared power to dispose or to direct the disposition of:

    427

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Barclays PLC
     
    Signature:Ramya Rao
    Name/Title:Director
    Date:05/13/2025
    Get the next $FLGT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    8/5/2021$55.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    SEC Filings

    See more
    • Fulgent Genetics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

      5/15/25 4:17:39 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

      SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      5/13/25 4:30:21 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

      SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      5/6/25 4:04:55 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and Treasurer Kim Paul bought $1,596,470 worth of shares (100,000 units at $15.96), increasing direct ownership by 40% to 348,282 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      3/5/25 6:47:40 PM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

      PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

      6/10/24 1:00:00 AM ET
      $FLGT
      $NEO
      Medical Specialities
      Health Care
      Precision Instruments
    • Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

      After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures,  PV Capital Management, and Catalyst Health Ventures.

      5/14/24 9:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Financials

    Live finance-specific insights

    See more
    • Fulgent Reports First Quarter 2025 Financial Results

      Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

      5/2/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

      Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a te

      4/10/25 4:05:00 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

      Full Year Total Revenue of $283.5 million Full Year Core Revenue grows 7% year-over-year to $281.2 million Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9

      2/28/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care

    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

      SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      11/5/24 4:46:55 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

      SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      1/23/24 4:13:58 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

      SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

      1/26/23 8:52:11 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Director Marsh Linda was granted 8,982 shares, increasing direct ownership by 48% to 27,641 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 7:29:07 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Director Nohaile Michael was granted 4,491 shares, increasing direct ownership by 31% to 19,020 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 5:32:58 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • Director Groves Regina E was granted 8,982 shares, increasing direct ownership by 112% to 16,982 units (SEC Form 4)

      4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

      5/19/25 5:32:32 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • UBS initiated coverage on Fulgent Genetics with a new price target

      UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

      12/7/23 6:19:41 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Genetics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

      12/8/22 7:45:09 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Raymond James initiated coverage on Fulgent Genetics with a new price target

      Raymond James initiated coverage of Fulgent Genetics with a rating of Outperform and set a new price target of $45.00

      11/18/22 7:49:05 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent Reports First Quarter 2025 Financial Results

      Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

      5/2/25 7:00:00 AM ET
      $FLGT
      Medical Specialities
      Health Care
    • Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

      Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a te

      4/10/25 4:05:00 PM ET
      $FLGT
      Medical Specialities
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance